NCT05823285View on ClinicalTrials.gov

A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients

PHASE1RecruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

March 22, 2023

Primary Completion Date

June 15, 2025

Study Completion Date

June 15, 2027

Conditions

Advanced Solid Tumors

Interventions

DRUG

QLS31903

0.01μg/kg-2.16 μg/kg QLS31903 for injection

Trial Locations (1)

200000

RECRUITING

Fudan Zhongshan Hospital, Shanghai

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY